Densitometric simultaneous estimation of combination of empagliflozin, linagliptin and metformin hydrochloride used in the treatment of type 2 diabetes mellitus

被引:0
|
作者
Ishita M. Patel
Usmangani K. Chhalotiya
Harsha D. Jani
Devansh Kansara
Dimal A Shah
机构
[1] Indukaka Ipcowala College of Pharmacy,Department of Pharmaceutical Chemistry and Analysis
[2] Babaria Institute of Pharmacy,undefined
关键词
Metformin HCl; Empagliflozin; Linagliptin; High-performance thin-layer chromatography; Validation;
D O I
暂无
中图分类号
学科分类号
摘要
A sensitive, accurate, precise, and robust high-performance thin-layer chromatography (HPTLC) method has been developed for the simultaneous quantification of empagliflozin, linagliptin, and metformin HCl in bulk and synthetic mixture. The method applied HPTLC aluminum plates pre-coated with silica gel 60 F254 as the stationary phase along with n-butanol:water:glacial acetic acid (6:3:1, v/v) as the mobile phase. The Rf values of empagliflozin, linagliptin, and metformin HCl were found to be 0.73, 0.52, and 0.33, respectively. Densitometric analysis was carried out in the absorbance mode at 223 nm. The method was obtained linear in the range of 0.1–0.7 μg/band for empagliflozin, 0.05–0.35 μg/band for linagliptin, and 10–70 μg/band for metformin HCl, respectively. From synthetic mixture, the percentage (%) amounts of all three drugs were found to be more than 98% by the proposed HPTLC method. The method was validated as per the International Conference on Harmonisation (ICH) guideline Q2(R1).
引用
收藏
页码:109 / 118
页数:9
相关论文
共 50 条
  • [21] Jentadueto™ (linagliptin/metformin HCl) tablets in the Management and Treatment of Adults With Type 2 Diabetes Mellitus
    Schwartz, Stanley
    ENDOCRINE PRACTICE, 2012, 18 (02) : A1 - A14
  • [22] Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
    Holland, Daniel Q.
    Neumiller, Joshua J.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 277 - 288
  • [23] Efficacy and safety of linagliptin and metformin combination compared with metformin alone on stratified approach of type 2 diabetes treatment
    Shi, Y.
    Walt, S. V. D.
    Miao, L.
    DIABETOLOGIA, 2018, 61 : S378 - S378
  • [24] Review of Linagliptin for the Treatment of Type 2 Diabetes Mellitus
    Neumiller, Joshua J.
    Setter, Stephen M.
    CLINICAL THERAPEUTICS, 2012, 34 (05) : 993 - 1005
  • [25] Combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with Type 2 diabetes
    Defronzo, R. A.
    Lewin, A.
    Patel, S.
    Liu, D.
    Kaste, R.
    Woerle, H. J.
    Broedl, U. C.
    DIABETIC MEDICINE, 2015, 32 : 90 - 90
  • [26] Options for empagliflozin in combination therapy in type 2 diabetes mellitus
    Hershon, Kenneth S.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 : 155 - 172
  • [27] Simultaneous quantification of empagliflozin, linagliptin and metformin hydrochloride in bulk and synthetic mixture by RP-LC method
    Patel, Ishita M.
    Chhalotiya, Usmangani K.
    Jani, Harsha D.
    Kansara, Devansh
    Kachhiya, Hetaben M.
    Shah, Dimal A.
    FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 7 (01)
  • [28] Combination of empagliflozin and linagliptin improves blood pressure and vascular function in type 2 diabetes
    Jung, Susanne
    Bosch, Agnes
    Kannenkeril, Dennis
    Karg, Marina, V
    Striepe, Kristina
    Bramlage, Peter
    Ott, Christian
    Schmieder, Roland E.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2020, 6 (06) : 364 - 371
  • [29] NETWORK META-ANALYSIS TO ASSESS THE RELATIVE EFFICACY AND SAFETY OF LINAGLIPTIN, EMPAGLIFLOZIN AND THE FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Daacke, I
    Kanters, S.
    Thorlund, K.
    Tebboth, A.
    VALUE IN HEALTH, 2016, 19 (07) : A667 - A667
  • [30] The safety of empagliflozin plus metformin for the treatment of type 2 diabetes
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (08) : 837 - 848